In vitro effects of tacrolimus on human cytochrome P450

Fundamental and Clinical Pharmacology

Volumn 16, Issue 6, 2002, Pages 455-460

  Lecointre, K ^a   Furlan, Valerie ^a   Taburet, A M ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Cytochrome P450; Immunosuppressant; In vitro; Liver; Metabolism; Tacrolimus

Indexed keywords

ALPHA NAPHTHOFLAVONE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 INHIBITOR; DEXTROMETHORPHAN; DIETHYLTHIOCARBAMATE; DRUG METABOLITE; ETHOXYRESORUFIN; HYDROXYTOLBUTAMIDE; KETOCONAZOLE; KETONAZOLE; LIDOCAINE; MEPHENYTOIN; MIDAZOLAM; PILOCARPINE; QUINIDINE; RESORUFIN; RITONAVIR; SULFAPHENAZOLE; TACROLIMUS; TOLBUTAMIDE; UMBELLIFERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER METABOLISM; METABOLITE; PRIORITY JOURNAL; DOSE RESPONSE; DRUG INTERACTION; KINETICS; LIVER MICROSOME; METABOLISM;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; TACROLIMUS;

EID: 0036456710     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2002.00114.x     Document Type: Article

References (31)

1. Plosker G.L., Foster R.H. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs (2000) 11 323-389.
2. Sattler M., Guengerich F.P., Yun C.H., Christians U., Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. (1992) 20 753-761.
3. Moller A., Iwasaki K., Kawamura A. et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab. Dispos. (1999) 27 633-636.
4. Furlan V., Perello L., Jaquemin E., Debray D., Taburet A.M. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation (1995) 59 1217-1218.
5. Furlan V., Parquin F., Penaud J.F. et al. Interaction between tacrolimus and itraconazole in a heart-lung recipient. Transplant. Proc. (1998) 30 187-188.
6. Wu Y.M., Venkataramanan R., Suzuki M. et al. Interaction between FK 506 and cyclosporine in dogs. Transplant. Proc. (1991) 23 2797-2799.
7. Furlan V., Debray D., Fourre C., Taburet A.M. Conversion from cyclosporin A to tacrolimus in pediatric liver transplantation. Pediatr. Transplantation (2000) 4 207-210.
8. Izuishi K., Wakabayashi H., Ohnishi T., Maeta H., Maeba T., Ichikawa Y. Effects of an immunosuppressive agent, tacrolimus (FK506), on the activities of cytochrome P-450-linked monoxygenase systems in rat liver microsomes. Int. J. Biochem. Cell. Biol. (1997) 29 921-928.
9. Dragacci S., Thomassin J., Magdalou J., Souhaili El Amri H., Boissel P., Siest G. Properties of human hepatic UDP-glucuronosyltransferases. Relationship to other inducible enzymes in patients with cholestasis. Eur. J. Clin. Pharmacol. (1987) 32 485-491.
10. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. (1976) 72 248-254.
11. Gilette J.R. Techniques for studying drug metabolism in vitro, in: La Du, B.N., Mandel, H.G., Way, E.L. (Eds.), Fundamentals of Drug Metabolism and Drug Disposition, Waverly Press, Baltimore, 1971, pp. 400-416.
12. Pohl R.J., Fouts J.R. A rapid method for assaying the metabolism of 7 -ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem. (1980) 107 150-155.
13. Maenpaa J., Sigusch H., Raunio H. et al. Differential inhibition of coumarin-7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. (1993) 45 1035-1042.
14. Miners J.O., Smith K.J., Robson R.A., McManus M.E., Veronese M.E., Birkett D.J. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. (1988) 37 1137-1144.
15. Goldstein J.A., Faletto M.B., Romkes-Sparks M. et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry (1994) 33 1743-1752.
16. Dayer P., Leemann T., Striberni P. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 db 1 activity. Clin. Pharmacol. Ther. (1989) 45 34-40.
17. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450 2E1. Chem. Res. Toxicol. (1990) 3 566-573.
18. Puglisi C.V., Pao J., Ferrara F., De Silva J.A. Determination of midazolam (Versed®) and its metabolites in plasama by high-performance liquid chromatography. J. Chromatogr. (1985) 344 199-209.
19. Bargetzi M.J., Aoyama T., Gonzalez F.J., Meyer U.A. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. Clin. Pharmacol. Ther. (1989) 46 521-527.
20. Meier U.T., Kronbach T., Meyer U.A. Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography. Anal. Biochem. (1985) 151 286-291.
21. Gorski J.C., Hall S.D., Jones D.R., VandenBranden M., Wrighton S.A. Regioselective biotranformation of midazolam by members of the human cytochrome P450, 3A (CYP3A) subfamily. Biochem. Pharmacol. (1994) 47 1643-1653.
22. Yun C.H., Shimada T., Guengerich F.P. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol. Pharmacol. (1991) 40 679-685.
23. Linweaver A., Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. (1934) 56 658.
24. Dixon M. The determination of enzyme inhibition constants. Biochem. J. (1953) 55 170-171.
25. Bourrie M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. (1996) 277 321-332.
26. Transon C., Lecoeur S., Leemann T., Beaune P., Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isoenzymes. Eur. J. Clin. Pharmcol. (1996) 51 79-85.
27. Wrighton S.A., Vandenbranden M., Stevens J.C. et al. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development. Drug Metab. Rev. (1993) 24 453-484.
28. Wandel C., Bôcker R., Bôhere H., Rûgheimer E., Martin E. Midazolam is metabolized by at least three different cytocfrome P450 enzymes. Br. J. Anaest. (1994) 73 658-661.
29. Thummel K.E., Shen D.D., Podoll T.D. et al. Use of midazolam as a human cytochrome P450, 3A probe. II. Characterization of inter- and intraindividual hepatic CYP3A4. Variability after liver transplantation. JPET (1994) 271 557-556.
30. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. (1997) 32 210-258.
31. Rao U.S., Sacrborough G.A. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of human P-glycoprotein. Mol. Pharmacol. (1994) 45 773-776.